SCHEMBL3154242

SCHEMBL3154242

CN(C)CC(=O)NC1CCC(NC(=O)C(F)(F)F)CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.43
MAOA P21397 1/20 0.40
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39
GAA P10253 1/20 0.36
EPHX1 P07099 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35
MEN1 O00255 1/20 0.35
TSHR P16473 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD11B1 P28845 1/20 0.35
MAPT P10636 1/20 0.34
SMO Q99835 1/20 0.34
PIK3CD O00329 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HPGD P15428 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4191188 0.86 MAOA (0.47) MAOAGAAEPHX1NPSR1KMT2A
Trifluoroacetic Acid SCHEMBL3154245 0.81 SMYD3 (0.42) MAOAGAAEPHX1
SCHEMBL12819982 0.81 MAOA (0.42) MAOAGAAEPHX1NPSR1KMT2A
SCHEMBL993860 0.80 PKM (0.61) PKMPDK1PDK2PDK3PDK4
Trifluoroacetic Acid SCHEMBL3154236 0.79 MME (0.39) MAOAGAAEPHX1TSHRMAPT
SCHEMBL9027748 0.79 EPHX1 (0.48) MAOAGAAEPHX1TSHRMAPT
SCHEMBL9027751 0.79 EPHX1 (0.48) MAOAGAAEPHX1TSHRMAPT
SCHEMBL9029685 0.79 EPHX1 (0.48) MAOAGAAEPHX1TSHRMAPT
SCHEMBL1908699 0.79 MAOA (0.43) MAOAGAAEPHX1NPSR1KMT2A
SCHEMBL3150142 0.77 PKM (0.47) PKMPDK1PDK2PDK3PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2012759-B1 PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2010-03-10 EP disclosed
US-20090093633-A1 Organic Compounds NOVARTIS AG 2009-04-09 US disclosed
EP-1841768-B1 PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2008-11-12 EP disclosed
US-20080207648-A1 Organic Compounds NOVARTIS AG (CH) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093633-A1 Organic Compounds ADORA2A, ADORA3, ADORA1 PKM 1100/4885MAOA 128/4885PDK1 880/4885
US-20080207648-A1 Organic Compounds ADORA2A, ADORA1, ADORA3 PKM 3223/4885MAOA 369/4885PDK1 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.